GARNET: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

• Sponsor: Tesaro, Inc. (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT02715284
• Collaborator: (none)
• Enrollment: 740
• Locations: 106
• Arms: 7
• Anticipated Duration (Months): 100.8
• Patients Per Site: 7
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of the study will examine the safety and clinical activity of dostarlimab in cohorts of participants with specific types of advanced solid tumors.

Condition or Disease	Intervention/Treatment	Phase
Neoplasms	Biological: Dostarlimab	Phase 1

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 740 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
• Actual Study Start Date: Mar 7, 2016
• Anticipated Primary Completion Date: Jul 30, 2024
• Anticipated Study Completion Date: Jul 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Part 1: Participants receiving dostarlimab Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
Experimental: Part 2A: Participants receiving dostarlimab In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
Experimental: Part 2B: Cohort A1 dMMR/MSI-H Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >= IIIB) disease.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
Experimental: Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >=IIIB) disease.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
Experimental: Part 2B: Cohort E NSCLC Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
Experimental: Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers Participants with recurrent or advanced dMMR/MSI-H solid tumors or polymerase ɛ mutated (POLE -mut) solid tumors , except endometrial cancers, that have progressed following up to 2 prior lines of systemic therapy for recurrent or advanced (>=Stage IIIB) disease and who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.
Experimental: Part 2B: Cohort G PROC without known BRCA Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.	Biological: Dostarlimab; Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.

Outcome Measures

Primary Outcome Measures

1. Part 1: Number of participants with treatment emergent AEs (TEAEs) [Up to 2 years]

   An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment.

2. Part 1: Number of participants with immune related AEs of interest [Up to 2 years]

   Participants with immune related AEs of interest will be assessed.

3. Part 1: Number of participants with abnormal hematology parameters [Up to 2 years]

   Blood samples will be collected to assess the following hematology parameters: hemoglobin, Mean corpuscular (MCV), white blood cell count (WBC count), platelets, mean platelet volume, differential WBC count and coagulation factors including International normalized ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT).

4. Part 1: Number of participants with abnormal clinical chemistry parameters [Up to 2 years]

   Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or blood urea nitrogen (BUN), amylase, bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total protein, albumin, lactate dehydrogenase.

5. Part 1: Number of participants with abnormal thyroid function [Up to 2 years]

   Blood samples will be collected to assess the levels of thyroid-stimulating hormone (TSH); triiodothyronine (T3), or free triiodothyronine (FT3) and free thyroxine (FT4).

6. Part 1: Number of participants with abnormal urine parameters [Up to 2 years]

   Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, protein, glucose, and ketones.

7. Part 1: Number of participants with abnormal vital signs [Up to 2 years]

   Blood pressure, pulse rate, respiratory rate and temperature will be assessed.

8. Part 1: Number of participants with abnormal electrocardiogram (ECG) parameters [Up to 2 years]

   Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.

9. Part 1: Number of participants with abnormal physical examination. [Up to 2 years]

   Physical examinations including weight will be assessed.

10. Part 1: Number of participants receiving concomitant medications [Up to 2 years]

    Concomitant medications will be recorded.

11. Part 2A: Number of participants with TEAEs [Up to 2 years]

    An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first dose of study treatment.

12. Part 2A: Number of participants with immune related AEs of interest [Up to 2 years]

    Participants with immune related AEs of interest will be assessed.

13. Part 2A: Number of participants with abnormal hematology parameters [Up to 2 years]

    Blood samples will be collected to assess the following hematology parameters: hemoglobin, MCV, white WBC count, platelets, mean platelet volume, differential WBC count and coagulation factors including INR, aPTT and PT.

14. Part 2A: Number of participants with abnormal clinical chemistry parameters [Up to 2 years]

    Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or BUN, amylase, bilirubin, AST, ALT, total protein, albumin, lactate dehydrogenase.

15. Part 2A: Number of participants with abnormal thyroid function [Up to 2 years]

    Blood samples will be collected to assess the levels of TSH, T3, or FT3 and FT4.

16. Part 2A: Number of participants with abnormal urine parameters [Up to 2 years]

    Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, protein, glucose, and ketones.

17. Part 2A: Number of participants with abnormal vital signs [Up to 2 years]

    Blood pressure, pulse rate, respiratory rate and temperature will be assessed.

18. Part 2A: Number of participants with abnormal ECG [Up to 2 years]

    Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.

19. Part 2A: Number of participants with abnormal physical examination [Up to 2 years]

    Physical examination including weight will be assessed.

20. Part 2A: Number of participants receiving concomitant medications [Up to 2 years]

    Concomitant medications will be recorded.

21. Part 2B: Number of participants with TEAEs [Up to 2 years]

    An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including clinically significant abnormal laboratory findings), symptom, or disease temporally associated with the use of an investigational product, whether or not considered related to the product. TEAEs defined as any AE either reported for the first dose of study treatment.

22. Part 2B: Number of participants with immune related AEs of interest [Up to 2 years]

    Participants with immune related AEs of interest will be assessed.

23. Part 2B: Number of participants with abnormal hematology parameters [Up to 2 years]

    Blood samples will be collected to assess the following hematology parameters: hemoglobin, MCV, white WBC count, platelets, mean platelet volume, differential WBC count and coagulation factors including INR, aPTT and PT.

24. Part 2B: Number of participants with abnormal clinical chemistry parameters [Up to 2 years]

    Blood samples will be collected to assess the following chemistry parameters: sodium, potassium, calcium, magnesium, chloride, glucose, creatinine, urea or BUN, amylase, bilirubin, AST, ALT, total protein, albumin, lactate dehydrogenase.

25. Part 2B: Number of participants with abnormal thyroid function [Up to 2 years]

    Blood samples will be collected to assess the levels of TSH, T3, or FT3 and FT4.

26. Part 2B: Number of participants with abnormal urine parameters [Up to 2 years]

    Urine samples will be collected to evaluate specific gravity, leucocyte esterase, nitrite, blood, protein, glucose, and ketones.

27. Part 2B: Number of participants with abnormal vital signs [Up to 2 years]

    Blood pressure, pulse rate, respiratory rate and temperature will be assessed.

28. Part 2B: Number of participants with abnormal ECG parameters [Up to 2 years]

    Participants will be supine or in a semi-recumbent position and rested for approximately 2 minutes before ECGs are recorded.

29. Part 2B: Number of participants with abnormal physical examination [Up to 2 years]

    Physical examinations including weight will be assessed.

30. Part 2B: Number of participants receiving concomitant medications [Up to 2 years]

    Concomitant medications will be recorded.

31. Part 2B: Cohort A1 Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [Up to 2 years]

    ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by investigator per RECIST version 1.1 will be evaluated.

32. Part 2B: Cohort F ORR by RECIST version 1.1 [Up to 2 years]

    ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per RECIST version 1.1 will be evaluated.

33. Part 2B: Cohort A2 ORR by RECIST version 1.1 [Up to 2 years]

    ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per RECIST version 1.1 will be evaluated.

34. Part 2B: Cohort G ORR by RECIST version 1.1 [Up to 2 years]

    ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per RECIST version 1.1 will be evaluated.

35. Part 2B: Cohort E ORR by immune related Response Evaluation Criteria in Solid Tumors per irRECIST [Up to 2 years]

    ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per irRECIST will be evaluated.

36. Part 2B: Cohort A1 Duration of response (DOR) [Up to 2 years]

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of progressive disease (PD) evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

37. Part 2B: Cohort F Duration of response (DOR) [Up to 2 years]

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

38. Part 2B: Cohort A2 Duration of response (DOR) [Up to 2 years]

    DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

Secondary Outcome Measures

1. Part 2B: Cohort A1 ORR by independent blinded central review using RECIST version 1.1 [Up to 2 years]

   ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per RECIST version 1.1 will be evaluated.

2. Part 2B: Cohort F ORR by independent blinded central review using RECIST version 1.1 [Up to 2 years]

   ORR is defined as the proportion of participants achieving CR or PR as assessed by investigator per RECIST version 1.1 will be evaluated.

3. Part 2B: Cohort A1 Immune-related objective response rate (irORR) by irRECIST [Up to 2 years]

   Immune related objective response rate will be evaluated.

4. Part 2B: Cohort A2 irORR by irRECIST [Up to 2 years]

   Immune related objective response rate will be evaluated.

5. Part 2B: Cohort F irORR by irRECIST [Up to 2 years]

   Immune related objective response rate will be evaluated.

6. Part 2B: Cohort G irORR by irRECIST [Up to 2 years]

   Immune related objective response rate will be evaluated.

7. Part 2B: Cohort A1 Duration of response (DOR) based on independent blinded central review using RECIST version 1.1 [Up to 2 years]

   DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of progressive disease (PD) evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

8. Part 2B: Cohort F DOR based on independent blinded central review using RECIST version 1.1 [Up to 2 years]

   DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

9. Part 2B: Cohort G DOR based on independent blinded central review using RECIST version 1.1 [Up to 2 years]

   DOR is defined as the time from first documentation of CR or PR by RECIST version 1.1 until the time of first documentation of PD evaluated using RECIST version 1.1 based on independent blinded central review, or death due to any cause.

10. Part 2B: Cohort A1 Disease control rate [Up to 2 years]

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

11. Part 2B: Cohort A2 Disease control rate [Up to 2 years]

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

12. Part 2B: Cohort F Disease control rate [Up to 2 years]

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

13. Part 2B: Cohort G Disease control rate [Up to 2 years]

    Disease control rate is the proportion of participants achieving CR, PR, or SD per RECIST v1.1 based on independent blinded central review.

14. Part 2B: Immune related disease control rate [Up to 2 years]

    The proportion of participants achieving CR, PR, or SD per irRECIST based on Investigators' assessment.

15. Part 2B: Immune related duration of response [Up to 2 years]

    The time from first documentation of CR or PR by irRECIST until the time of first documentation of PD (subsequently confirmed) per irRECIST based on Investigators' assessment.

16. Part 2B: Progression free survival [Up to 2 years]

    The time from date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression based on: (1) the time of first documentation of PD per RECIST v1.1 (for Cohorts A1, A2, F, and G only); and (2) the time of first documentation of PD (subsequently confirmed) per irRECIST.

17. Part 2B: Overall survival [Up to 2 years]

    The time from date of first dose of study treatment to the date of death by any cause.

18. Part 1: Area under the concentration-time curve from time 0 to last (AUC,0-last) assessment of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504 and 672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

19. Part 1: Area under the concentration-time curve from time 0 to infinity (AUC, 0-infinity) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

20. Part 1: Minimum concentration (Cmin) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

21. Part 1: Maximum concentration (Cmax) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

22. Part 1: Clearance (CL) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

23. Part 1: Volume of distribution (Vz) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

24. Part 1: Area under the concentration-time curve at steady state (AUC,ss) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

25. Part 1: Minimum concentration at steady state (Cmin,ss) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose.]

    Blood samples for determination of serum levels of dostarlimab will be collected.

26. Part 1: Maximum concentration at steady state (Cmax,ss) of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

27. Part 2A : AUC,0-last assessment of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

28. Part 2A: AUC, 0-infinity of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

29. Part 2A: Cmin of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected

30. Part 2A: Cmax of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

31. Part 2A: CL of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

32. Part 2A: Vz of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years.]

    Blood samples for determination of serum levels of dostarlimab will be collected.

33. Part 2A: AUC,ss of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

34. Part 2A: Cmin,ss of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

35. Part 2A: Cmax,ss of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

36. Part 2A : AUC,0-last assessment of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

37. Part 2A: AUC, 0-infinity of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

38. Part 2A: Cmin of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

39. Part 2A: Cmax of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

40. Part 2A: CL of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

41. Part 2A: Vz of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

42. Part 2A: AUC,ss of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

43. Part 2A: Cmin,ss of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

44. Part 2A: Cmax,ss of dostarlimab [Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840 and 1008 hours post dose Q6W upto 2 years]

    Blood samples for determination of serum levels of dostarlimab will be collected.

45. Part 2B : AUC,0-last assessment of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

46. Part 2B: AUC, 0-infinity of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

47. Part 2B: Cmin of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

48. Part 2B: Cmax of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

49. Part 2B: CL of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

50. Part 2B: Vz of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

51. Part 2B: AUC,ss of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

52. Part 2B: Cmin,ss of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

53. Part 2B: Cmax,ss of dostarlimab [Predose, 0.5 and 1.5 hours post dose]

    Blood samples for determination of serum levels of dostarlimab will be collected.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Participant is at least 18 years of age.

• Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anti cancer therapies, or is intolerant to treatment that meets the following requirements for the part of the study they will participate in:

• 1. Part 1: Any histologically or cytologically proven recurrent advanced solid tumor
• 1. Part 2A: : Any histologically or cytologically proven recurrent advanced solid tumor
• 1. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor with measurable lesion(s) per RECIST version 1.1 and meets one of the following disease types:

• The criteria below should be met for participant participating in:

• Cohort A1 (dMMR/MSI-H endometrial cancer) and

• Cohort A2 (MMR-proficient/MSS endometrial cancer)

• Participants who have progressed on or after platinum doublet therapy

• Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (>=Stage IIIB) disease. Prior treatment with hormone therapies is acceptable and does not count towards the number of anti-cancer therapies noted in the criterion above for this cohort.

• All endometrial cancer histologies are allowed except endometrial sarcoma (including carcinosarcoma).

• Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD on or after the latest systemic anti-cancer therapy based on RECIST 1.1 to Central Radiology prior to the first dose of dostarlimab.

• Presence of at least 1 measurable lesion on Baseline scan will be confirmed by central radiology review.

• Status of tumor MMR/MSI: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participant with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to Cycle 1 Day 1 (C1D1). For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing.

• Cohort E - Participants with NSCLC who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease.

• Chemotherapy regimen in the adjuvant or neoadjuvant setting following surgery and/or radiation is acceptable if recurrent or advanced disease develops within 6 months from completion of therapy.

• Participants with a known epidermal growth factor receptor (EGFR) mutation must have received a chemotherapy regimen and an EGFR tyrosine-kinase inhibitor (TKI) (e.g., erlotinib, gefitinib, afatinib, or experimental)

• Participants with a known anaplastic lymphoma kinase (ALK) translocation must have received a chemotherapy regimen and an ALK inhibitor (e.g., crizotinib, ceritinib or experimental)

• Cohort F - Participants with recurrent or advanced dMMR/MSI-H solid tumors or POLE-mut solid tumors, except endometrial cancers, that have progressed following up to 2 prior lines of systemic therapy for recurrent or advanced (>=Stage IIIB) disease and who have no alternative treatment options. Prior treatment with hormone therapies alone given for recurrent or advanced disease is acceptable and does not count towards the number of anti-cancer therapies.

• dMMR/MSI-H colorectal cancer (CRC) participants must have progressed after or been intolerant to treatment with fluoropyrimidine, oxaliplatin, and irinotecan. Progression following up to 3 prior lines of therapy is allowed.

• Ovarian cancer participants with platinum-resistant disease (i.e., progression occurred <6 months on or after platinum doublet chemotherapy): receipt of up to 1 line of systemic therapy after becoming platinum-resistant is allowed.

• Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD based on RECIST 1.1 to Central Radiology prior to the first dose of dostarlimab.

• Tumor MMR/MSI or POLE status: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participants with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to C1D1. For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing.

• Participants who are considered for the study based on POLE mutation must have the local results available showing tumor mutation(s) in the exonuclease domain of the POLE gene (amino acid residues 268-471) to begin screening. Participants must have the quality of submitted tumor samples checked and cleared by a central IHC laboratory prior to receiving study treatment.

• Cohort G: Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer.

• Participants must have presence of at least 1 measurable lesion on Baseline scan that will be confirmed by central radiology review.

• Participants must be considered resistant to the last administered platinum therapy, that is, the time from the last administered platinum dose until the initial documented progression (as evidenced by radiographic progression per RECIST) must be less than 6 months.

• Participants must have completed at least 1 but no more than 3 prior lines of therapy for advanced or metastatic ovarian cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as 1 line of therapy. Treatment with single-agent bevacizumab given as maintenance is not counted as a separate line of therapy. If a therapeutic regimen is modified or changed for a reason other than lack of response or PD (such as allergic reaction, toxicity, or drug availability), this is not counted as a separate line of therapy. The use of single-agent hormonal therapy given for reasons other than PD per RECIST v1.1 (i.e., hormonal therapy given for increasing Cancer antigen [CA]-125 levels) is not counted as a separate line of therapy.

• Participants must have been previously treated with platinum-based regimen, taxane agent(s), and bevacizumab (bevacizumab could be used as a single agent or in combination with another agent, in frontline therapy, as maintenance, or for treatment of recurrent disease).

• Part 2B: Participants must have archival tumor tissue available that is formalin-fixed and paraffin-embedded.

• For participants who do not have archival tissue, a new biopsy must be performed to obtain a tissue sample prior to study treatment initiation. For participants without available archival tissue, the biopsy should be taken from the tumor lesions (either primary or metastatic) that have easy accessibility and low biopsy-associated risks and will exclude biopsies of the liver, brain, lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach or bowel.

• For Cohort G, participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable, for example, measures of homologous recombination pathway defects and PD-L1 status. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor.

• Female participants must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication: unless they are of non-child bearing potential.

• Non child bearing potential is defined as: >= 45 years of age and has not had menses for > 1 year; Amenorrheic for < 2 years without a hysterectomy and oophorectomy and have a follicle- stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) scan. Tubal ligation must be confirmed with medical records of the actual procedure.

• Female participants of childbearing potential must agree to use 1 highly effective form of contraception with their partner starting with the screening visit through 150 days after the last dose of study therapy.

• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2 for Part 1 and <= 1 for Part 2.

• Participant has an adequate organ function.

Exclusion Criteria

• Participant has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent.

• Participant has a known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

• Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).

• Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.

• Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.

• Participant has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).

• Participant has a known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid (HCV RNA) (qualitative) is detected).

• Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease- modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.

• Participant has as history of interstitial lung disease.

• Participant has not recovered (i.e., to <= Grade 1 or to Baseline) from radiation- and chemotherapy-induced AEs or received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 3 weeks prior to the first dose of study drug.

• Participant has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study drug.

• Participant has received prior anti-cancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half-life of the most recent therapy prior to study Day 1, whichever is shorter.

• Participant has not recovered adequately (<= Grade 1) from AEs and/or complications from any major surgery prior to starting therapy.

• Participant has received a live vaccine within 14 days of planned start of study therapy.

• Participant has a known hypersensitivity to dostarlimab components or excipients.

• For Cohort G, participants will not be eligible if they meet the following criteria:

• Participants who experienced disease progression within 3 months (as evidenced by radiographic progression per RECIST) of first-line platinum therapy.

• Participants with known deleterious or suspicious deleterious mutation in BRCA1 or BRCA2 genes (local testing permitted).

• Participants has received prior therapy with a poly(adenosine diphosphate-ribose) polymerase (PARP)-1/PARP-2 inhibitor.

• Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, might interfere with the participant's participation for the full duration of the study treatment, or is not in the best interest of the participant to participate.

• Participant is immunocompromised. Participants with splenectomy are allowed.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Birmingham	Alabama	United States	35233
2	GSK Investigational Site	Goodyear	Arizona	United States	85338
3	GSK Investigational Site	Scottsdale	Arizona	United States	85258
4	GSK Investigational Site	Fayetteville	Arkansas	United States	72703
5	GSK Investigational Site	Encinitas	California	United States	92024
6	GSK Investigational Site	La Jolla	California	United States	92093
7	GSK Investigational Site	Los Angeles	California	United States	90095
8	GSK Investigational Site	Newport Beach	California	United States	92663
9	GSK Investigational Site	Newport Beach	California	United States	92663
10	GSK Investigational Site	San Francisco	California	United States	94115
11	GSK Investigational Site	San Marcos	California	United States	92069
12	GSK Investigational Site	Santa Monica	California	United States	90403
13	GSK Investigational Site	Washington	District of Columbia	United States	20007
14	GSK Investigational Site	Miami	Florida	United States	33136
15	GSK Investigational Site	Tampa	Florida	United States	33612
16	GSK Investigational Site	Augusta	Georgia	United States	30912
17	GSK Investigational Site	Chicago	Illinois	United States	60637
18	GSK Investigational Site	Westwood	Kansas	United States	66205
19	GSK Investigational Site	Scarborough	Maine	United States	04074
20	GSK Investigational Site	Baltimore	Maryland	United States	21231
21	GSK Investigational Site	Boston	Massachusetts	United States	02114
22	GSK Investigational Site	Boston	Massachusetts	United States	02215
23	GSK Investigational Site	Detroit	Michigan	United States	48201
24	GSK Investigational Site	Kansas City	Missouri	United States	64111
25	GSK Investigational Site	Farmington	New Mexico	United States	87401
26	GSK Investigational Site	Albany	New York	United States	12208
27	GSK Investigational Site	Brooklyn	New York	United States	11203
28	GSK Investigational Site	Jamaica	New York	United States	11432
29	GSK Investigational Site	New York	New York	United States	10016
30	GSK Investigational Site	Charlotte	North Carolina	United States	28204
31	GSK Investigational Site	Cleveland	Ohio	United States	44106
32	GSK Investigational Site	Columbus	Ohio	United States	43210
33	GSK Investigational Site	Hilliard	Ohio	United States	43026
34	GSK Investigational Site	Oklahoma City	Oklahoma	United States	73104
35	GSK Investigational Site	Philadelphia	Pennsylvania	United States	19104
36	GSK Investigational Site	Philadelphia	Pennsylvania	United States	19111
37	GSK Investigational Site	Providence	Rhode Island	United States	02905
38	GSK Investigational Site	Dallas	Texas	United States	75230
39	GSK Investigational Site	Dallas	Texas	United States	75290-9032
40	GSK Investigational Site	San Antonio	Texas	United States	78229
41	GSK Investigational Site	San Antonio	Texas	United States	78229
42	GSK Investigational Site	Salt Lake City	Utah	United States	84112
43	GSK Investigational Site	Charlottesville	Virginia	United States	22903
44	GSK Investigational Site	Seattle	Washington	United States	98104
45	GSK Investigational Site	Seattle	Washington	United States	98195
46	GSK Investigational Site	Spokane	Washington	United States	99202
47	GSK Investigational Site	Spokane	Washington	United States	99204
48	GSK Investigational Site	Milwaukee	Wisconsin	United States	53226
49	GSK Investigational Site	Calgary	Alberta	Canada	T2N 4N2
50	GSK Investigational Site	Edmonton	Alberta	Canada	T6G 1Z2
51	GSK Investigational Site	Kelowna	British Columbia	Canada	V1Y 5L3
52	GSK Investigational Site	Vancouver	British Columbia	Canada	V5Z 4E6
53	GSK Investigational Site	Hamilton	Ontario	Canada	L8V 5C2
54	GSK Investigational Site	London	Ontario	Canada	N6A 4L6
55	GSK Investigational Site	Montreal	Quebec	Canada	H2L 4M1
56	GSK Investigational Site	Montreal	Quebec	Canada	H4A 3J1
57	GSK Investigational Site	Horovice		Czechia	26831
58	GSK Investigational Site	Zlin		Czechia	762 75
59	GSK Investigational Site	Copenhagen		Denmark	DK- 2100
60	GSK Investigational Site	Odense		Denmark	5000
61	GSK Investigational Site	Caen Cedex 05		France	14076
62	GSK Investigational Site	Lille		France	59000
63	GSK Investigational Site	Marseille Cedex 9		France	13273
64	GSK Investigational Site	Paris cedex 12		France	75571
65	GSK Investigational Site	Paris Cedex 15		France	75908
66	GSK Investigational Site	Saint-Herblain		France	44805
67	GSK Investigational Site	Villejuif		France	94805
68	GSK Investigational Site	Napoli	Campania	Italy	80131
69	GSK Investigational Site	Modena	Emilia-Romagna	Italy	41100
70	GSK Investigational Site	Roma	Lazio	Italy	00144
71	GSK Investigational Site	Milano	Lombardia	Italy	20132
72	GSK Investigational Site	Milano	Lombardia	Italy	20133
73	GSK Investigational Site	Milano	Lombardia	Italy	20141
74	GSK Investigational Site	Verona	Veneto	Italy	37134
75	GSK Investigational Site	MIlano		Italy	20133
76	GSK Investigational Site	Gdynia		Poland	81-519
77	GSK Investigational Site	Lublin		Poland	20-090
78	GSK Investigational Site	Olsztyn		Poland	10-513
79	GSK Investigational Site	Olsztyn		Poland	10-561
80	GSK Investigational Site	Torun		Poland	87-100
81	GSK Investigational Site	Barcelona		Spain	08036
82	GSK Investigational Site	Barcelona		Spain	08907
83	GSK Investigational Site	Barcelona		Spain	8035
84	GSK Investigational Site	Girona		Spain	17007
85	GSK Investigational Site	Hospitalet de Llobregat (Barcelona)		Spain	08907
86	GSK Investigational Site	Madrid		Spain	28027
87	GSK Investigational Site	Madrid		Spain	28040
88	GSK Investigational Site	Madrid		Spain	28040
89	GSK Investigational Site	Madrid		Spain	28046
90	GSK Investigational Site	Madrid		Spain	28050
91	GSK Investigational Site	Málaga		Spain	29010
92	GSK Investigational Site	Pamplona		Spain	31008
93	GSK Investigational Site	Santiago de Compostela		Spain	15706
94	GSK Investigational Site	Sevilla		Spain	41013
95	GSK Investigational Site	Valencia		Spain	46009
96	GSK Investigational Site	Valencia		Spain	46010
97	GSK Investigational Site	Zaragoza		Spain	50009
98	GSK Investigational Site	Aberdeen		United Kingdom	AB25 2ZN
99	GSK Investigational Site	Headington, Oxford		United Kingdom	OX3 7LE
100	GSK Investigational Site	London		United Kingdom	SE1 9RT
101	GSK Investigational Site	London		United Kingdom	SW3 6JJ
102	GSK Investigational Site	London		United Kingdom	SW36JJ
103	GSK Investigational Site	London		United Kingdom	W1G 6AD
104	GSK Investigational Site	London		United Kingdom	W1T 7HA
105	GSK Investigational Site	Manchester		United Kingdom	M20 4BX
106	GSK Investigational Site	Newcastle upon Tyne		United Kingdom	NE7 7DN

Sponsors and Collaborators

• Tesaro, Inc.

Investigators

• Study Director: GSK Clinical Trials, GlaxoSmithKline

Study Documents (Full-Text)

None provided.

More Information

Publications

• Kumar S, Ghosh S, Sharma G, Wang Z, Kehry MR, Marino MH, Neben TY, Lu S, Luo S, Roberts S, Ramaswamy S, Danaee H, Jenkins D. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136. doi: 10.1080/19420862.2021.1954136.
• Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022 Jan;10(1). pii: e003777. doi: 10.1136/jitc-2021-003777.
• Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, Guo W, Lu S, Danaee H, McEachern K, Im E, Sachdev JC. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. Cancer Chemother Pharmacol. 2022 Jan;89(1):93-103. doi: 10.1007/s00280-021-04358-3. Epub 2021 Nov 8.
• Patterson M, Beausang LA, Rup B, Bowsher R, Krug K, Gunn G, Melham M, Lu S.A Bridging Assay for Detection and Characterization of Anti-Drug Antibodies to Dostarlimab, a New Anti-PD-1 Therapeutic Monoclonal Antibody .2021;7(11) DOI: DOI 10.1186/s41120-021-00045-y
• Zhang XT, Chen H, Shao W, Zhongping JL, Melham M, Lu S.A Competitive Ligand Binding Assay to Measure Antidrug Antibodies Against Dostarlimab (TSR-042).2021; DOI: 10.1186/s41120-021-00039-w

• Responsible Party: Tesaro, Inc.
• ClinicalTrials.gov Identifier: NCT02715284
• Other Study ID Numbers: 213346; 4010-01-001
• First Posted: Mar 22, 2016
• Last Update Posted: Apr 7, 2022
• Last Verified: Mar 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Keywords provided by Tesaro, Inc.: Metastatic solid tumors; Advanced solid tumors; anti-PD-1; TSR-042; Immunotherapy; PD-1; Endometrial; Non-small cell lung cancer, NSCLC; MSI-High; Dostarlimab; dMMR

Study Results

No Results Posted as of Apr 7, 2022